AU2002254357A1

AU2002254357A1 - Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon

Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon Download PDF

Info

Publication number: AU2002254357A1
Authority: AU; Australia
Prior art keywords: polypeptide; sequence; cvsp14; nucleotides; nucleic acid
Prior art date: 2001-03-22
Legal status : Abandoned

Application number

AU2002254357A

Other languages

English (en)

Inventor

Edwin L. Madison

Jiunn-Chern Yeh

Current Assignee

Dendreon Corp

Original Assignee

Dendreon Corp

Priority date

2001-03-22

Filing date

2002-03-20

Publication date

2002-10-08

2002-03-20 Application filed by Dendreon Corp filed Critical Dendreon Corp

2002-10-08 Publication of AU2002254357A1 publication Critical patent/AU2002254357A1/en

2004-03-18 Assigned to DENDREON CORPORATION reassignment DENDREON CORPORATION Request for Assignment Assignors: DENDREON SAN DIEGO LLC

Status Abandoned legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 439
102000004196 processed proteins & peptides Human genes 0.000 title claims description 380
229920001184 polypeptide Polymers 0.000 title claims description 334
150000007523 nucleic acids Chemical class 0.000 title claims description 191
102000039446 nucleic acids Human genes 0.000 title claims description 185
108020004707 nucleic acids Proteins 0.000 title claims description 185
238000000034 method Methods 0.000 title claims description 184
108010022999 Serine Proteases Proteins 0.000 title description 172
102000012479 Serine Proteases Human genes 0.000 title description 165
108091005804 Peptidases Proteins 0.000 claims description 246
239000004365 Protease Substances 0.000 claims description 245
108090000623 proteins and genes Proteins 0.000 claims description 227
150000001875 compounds Chemical class 0.000 claims description 173
210000004027 cell Anatomy 0.000 claims description 168
230000000694 effects Effects 0.000 claims description 144
125000003729 nucleotide group Chemical group 0.000 claims description 121
239000002773 nucleotide Substances 0.000 claims description 116
235000001014 amino acid Nutrition 0.000 claims description 109
150000001413 amino acids Chemical class 0.000 claims description 95
206010028980 Neoplasm Diseases 0.000 claims description 90
239000003795 chemical substances by application Substances 0.000 claims description 83
238000012360 testing method Methods 0.000 claims description 82
239000012634 fragment Substances 0.000 claims description 65
230000027455 binding Effects 0.000 claims description 57
239000000758 substrate Substances 0.000 claims description 56
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
239000013598 vector Substances 0.000 claims description 51
239000000523 sample Substances 0.000 claims description 44
239000000126 substance Substances 0.000 claims description 43
210000001519 tissue Anatomy 0.000 claims description 39
241000282414 Homo sapiens Species 0.000 claims description 38
201000010099 disease Diseases 0.000 claims description 37
230000003197 catalytic effect Effects 0.000 claims description 36
241001465754 Metazoa Species 0.000 claims description 33
239000003112 inhibitor Substances 0.000 claims description 33
102000010911 Enzyme Precursors Human genes 0.000 claims description 31
108010062466 Enzyme Precursors Proteins 0.000 claims description 31
201000011510 cancer Diseases 0.000 claims description 30
230000004913 activation Effects 0.000 claims description 28
238000006467 substitution reaction Methods 0.000 claims description 28
230000002797 proteolythic effect Effects 0.000 claims description 25
230000000295 complement effect Effects 0.000 claims description 24
230000001225 therapeutic effect Effects 0.000 claims description 24
230000001613 neoplastic effect Effects 0.000 claims description 23
238000003776 cleavage reaction Methods 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 22
230000007017 scission Effects 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 20
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 17
241000124008 Mammalia Species 0.000 claims description 17
239000007787 solid Substances 0.000 claims description 17
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 15
102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 15
210000001124 body fluid Anatomy 0.000 claims description 15
239000010839 body fluid Substances 0.000 claims description 15
238000001514 detection method Methods 0.000 claims description 15
108020004999 messenger RNA Proteins 0.000 claims description 15
239000013604 expression vector Substances 0.000 claims description 13
230000008685 targeting Effects 0.000 claims description 13
230000008859 change Effects 0.000 claims description 12
238000000746 purification Methods 0.000 claims description 12
108091034117 Oligonucleotide Proteins 0.000 claims description 11
239000002246 antineoplastic agent Substances 0.000 claims description 11
230000012010 growth Effects 0.000 claims description 11
210000002307 prostate Anatomy 0.000 claims description 11
108020004705 Codon Proteins 0.000 claims description 10
206010060862 Prostate cancer Diseases 0.000 claims description 10
230000000692 anti-sense effect Effects 0.000 claims description 10
230000001580 bacterial effect Effects 0.000 claims description 10
230000002401 inhibitory effect Effects 0.000 claims description 10
210000004072 lung Anatomy 0.000 claims description 10
210000000481 breast Anatomy 0.000 claims description 9
238000002955 isolation Methods 0.000 claims description 9
230000005751 tumor progression Effects 0.000 claims description 9
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 8
239000012530 fluid Substances 0.000 claims description 8
210000003000 inclusion body Anatomy 0.000 claims description 8
210000004962 mammalian cell Anatomy 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
208000026310 Breast neoplasm Diseases 0.000 claims description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
208000029742 colonic neoplasm Diseases 0.000 claims description 7
230000003211 malignant effect Effects 0.000 claims description 7
241000238631 Hexapoda Species 0.000 claims description 6
206010061309 Neoplasm progression Diseases 0.000 claims description 6
206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 6
210000001072 colon Anatomy 0.000 claims description 6
210000003527 eukaryotic cell Anatomy 0.000 claims description 6
208000020816 lung neoplasm Diseases 0.000 claims description 6
230000001575 pathological effect Effects 0.000 claims description 6
239000000816 peptidomimetic Substances 0.000 claims description 6
150000003384 small molecules Chemical class 0.000 claims description 6
102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 5
239000012472 biological sample Substances 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
230000002255 enzymatic effect Effects 0.000 claims description 5
230000000977 initiatory effect Effects 0.000 claims description 5
238000012544 monitoring process Methods 0.000 claims description 5
210000001672 ovary Anatomy 0.000 claims description 5
230000028327 secretion Effects 0.000 claims description 5
210000002700 urine Anatomy 0.000 claims description 5
210000005253 yeast cell Anatomy 0.000 claims description 5
206010033128 Ovarian cancer Diseases 0.000 claims description 4
241000235648 Pichia Species 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
239000012190 activator Substances 0.000 claims description 4
239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
210000004102 animal cell Anatomy 0.000 claims description 4
230000001772 anti-angiogenic effect Effects 0.000 claims description 4
239000000074 antisense oligonucleotide Substances 0.000 claims description 4
238000012230 antisense oligonucleotides Methods 0.000 claims description 4
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
229930014626 natural product Natural products 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
210000001236 prokaryotic cell Anatomy 0.000 claims description 4
210000003296 saliva Anatomy 0.000 claims description 4
210000004243 sweat Anatomy 0.000 claims description 4
210000001179 synovial fluid Anatomy 0.000 claims description 4
230000009261 transgenic effect Effects 0.000 claims description 4
108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 3
206010003445 Ascites Diseases 0.000 claims description 3
210000003679 cervix uteri Anatomy 0.000 claims description 3
210000000805 cytoplasm Anatomy 0.000 claims description 3
238000006471 dimerization reaction Methods 0.000 claims description 3
238000002744 homologous recombination Methods 0.000 claims description 3
230000006801 homologous recombination Effects 0.000 claims description 3
208000023958 prostate neoplasm Diseases 0.000 claims description 3
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
208000006994 Precancerous Conditions Diseases 0.000 claims description 2
101710098606 Suppressor of tumorigenicity 14 protein homolog Proteins 0.000 claims description 2
210000003722 extracellular fluid Anatomy 0.000 claims description 2
238000002743 insertional mutagenesis Methods 0.000 claims description 2
230000003902 lesion Effects 0.000 claims description 2
230000036210 malignancy Effects 0.000 claims description 2
210000001138 tear Anatomy 0.000 claims description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 23
230000000259 anti-tumor effect Effects 0.000 claims 3
238000012258 culturing Methods 0.000 claims 2
WPVINHLVHHPBMK-ULQDDVLXSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[(2s)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCN1C(=O)[C@@H]1CCC(=O)N1 WPVINHLVHHPBMK-ULQDDVLXSA-N 0.000 claims 1
208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
238000001574 biopsy Methods 0.000 claims 1
239000003593 chromogenic compound Substances 0.000 claims 1
239000001963 growth medium Substances 0.000 claims 1
201000006385 lung benign neoplasm Diseases 0.000 claims 1
208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
102000035195 Peptidases Human genes 0.000 description 223
235000019419 proteases Nutrition 0.000 description 203
102000004169 proteins and genes Human genes 0.000 description 159
235000018102 proteins Nutrition 0.000 description 156
108020004414 DNA Proteins 0.000 description 84
230000014509 gene expression Effects 0.000 description 76
229940024606 amino acid Drugs 0.000 description 70
238000003556 assay Methods 0.000 description 58
210000004881 tumor cell Anatomy 0.000 description 41
239000000203 mixture Substances 0.000 description 34
230000009368 gene silencing by RNA Effects 0.000 description 32
238000000338 in vitro Methods 0.000 description 30
108091030071 RNAI Proteins 0.000 description 28
239000000047 product Substances 0.000 description 27
125000003275 alpha amino acid group Chemical group 0.000 description 26
238000012216 screening Methods 0.000 description 25
-1 small molecules Chemical class 0.000 description 24
239000003446 ligand Substances 0.000 description 23
102000004190 Enzymes Human genes 0.000 description 22
108090000790 Enzymes Proteins 0.000 description 22
229940088598 enzyme Drugs 0.000 description 22
239000003001 serine protease inhibitor Substances 0.000 description 21
230000033115 angiogenesis Effects 0.000 description 20
102000005962 receptors Human genes 0.000 description 20
108020003175 receptors Proteins 0.000 description 20
206010027476 Metastases Diseases 0.000 description 19
239000013612 plasmid Substances 0.000 description 18
230000009401 metastasis Effects 0.000 description 17
239000000243 solution Substances 0.000 description 17
238000009396 hybridization Methods 0.000 description 16
238000001727 in vivo Methods 0.000 description 16
239000013615 primer Substances 0.000 description 16
101710102218 Serine protease inhibitor Proteins 0.000 description 15
229940122055 Serine protease inhibitor Drugs 0.000 description 15
239000002299 complementary DNA Substances 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 14
208000035475 disorder Diseases 0.000 description 14
108010076504 Protein Sorting Signals Proteins 0.000 description 13
230000006870 function Effects 0.000 description 13
238000013518 transcription Methods 0.000 description 13
230000035897 transcription Effects 0.000 description 13
230000004071 biological effect Effects 0.000 description 12
239000000284 extract Substances 0.000 description 12
125000005647 linker group Chemical group 0.000 description 12
210000004882 non-tumor cell Anatomy 0.000 description 12
208000024891 symptom Diseases 0.000 description 12
238000003786 synthesis reaction Methods 0.000 description 12
239000003814 drug Substances 0.000 description 11
230000017854 proteolysis Effects 0.000 description 11
241000894007 species Species 0.000 description 11
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
238000011161 development Methods 0.000 description 10
230000018109 developmental process Effects 0.000 description 10
230000005714 functional activity Effects 0.000 description 10
239000002987 primer (paints) Substances 0.000 description 10
238000010561 standard procedure Methods 0.000 description 10
230000014616 translation Effects 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 9
206010029113 Neovascularisation Diseases 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 9
208000000236 Prostatic Neoplasms Diseases 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 9
102000018358 immunoglobulin Human genes 0.000 description 9
229940002612 prodrug Drugs 0.000 description 9
239000000651 prodrug Substances 0.000 description 9
238000007423 screening assay Methods 0.000 description 9
238000013519 translation Methods 0.000 description 9
241000196324 Embryophyta Species 0.000 description 8
241000282412 Homo Species 0.000 description 8
108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000012528 membrane Substances 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
230000008569 process Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
230000019491 signal transduction Effects 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
108020004511 Recombinant DNA Proteins 0.000 description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 7
210000002744 extracellular matrix Anatomy 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
238000010369 molecular cloning Methods 0.000 description 7
238000000159 protein binding assay Methods 0.000 description 7
235000019333 sodium laurylsulphate Nutrition 0.000 description 7
230000009870 specific binding Effects 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 6
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 6
108700039691 Genetic Promoter Regions Proteins 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 6
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
230000009400 cancer invasion Effects 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
230000009545 invasion Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
102000006240 membrane receptors Human genes 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
241000972773 Aulopiformes Species 0.000 description 5
108010001857 Cell Surface Receptors Proteins 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
101001008919 Homo sapiens Kallikrein-10 Proteins 0.000 description 5
102100027613 Kallikrein-10 Human genes 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 5
108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
102100038358 Prostate-specific antigen Human genes 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
206010064390 Tumour invasion Diseases 0.000 description 5
230000004075 alteration Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
238000013461 design Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
230000002538 fungal effect Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
238000013537 high throughput screening Methods 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000000099 in vitro assay Methods 0.000 description 5
108010082117 matrigel Proteins 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
235000019515 salmon Nutrition 0.000 description 5
102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 5
108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 5
230000002103 transcriptional effect Effects 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
208000005623 Carcinogenesis Diseases 0.000 description 4
108090000317 Chymotrypsin Proteins 0.000 description 4
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
229920001917 Ficoll Polymers 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
108010067902 Peptide Library Proteins 0.000 description 4
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
210000002469 basement membrane Anatomy 0.000 description 4
239000011324 bead Substances 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
238000006555 catalytic reaction Methods 0.000 description 4
229960002376 chymotrypsin Drugs 0.000 description 4
239000013599 cloning vector Substances 0.000 description 4
230000009089 cytolysis Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000007876 drug discovery Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
230000035772 mutation Effects 0.000 description 4
229950009865 nafamostat Drugs 0.000 description 4
238000011275 oncology therapy Methods 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
238000002823 phage display Methods 0.000 description 4
239000012071 phase Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
230000009467 reduction Effects 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000012552 review Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
230000005748 tumor development Effects 0.000 description 4
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical compound C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
241000282994 Cervidae Species 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241000724791 Filamentous phage Species 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
108090001101 Hepsin Proteins 0.000 description 3
102000004989 Hepsin Human genes 0.000 description 3
101710132360 Kunitz-type serine protease inhibitor Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
108010091175 Matriptase Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108090000526 Papain Proteins 0.000 description 3
241001494479 Pecora Species 0.000 description 3
241000282849 Ruminantia Species 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
241000282887 Suidae Species 0.000 description 3
FKMJXALNHKIDOD-LBPRGKRZSA-N TAMe Chemical compound NC(=N)NCCC[C@@H](C(=O)OC)NS(=O)(=O)C1=CC=C(C)C=C1 FKMJXALNHKIDOD-LBPRGKRZSA-N 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000003527 anti-angiogenesis Effects 0.000 description 3
238000011394 anticancer treatment Methods 0.000 description 3
210000004507 artificial chromosome Anatomy 0.000 description 3
238000002820 assay format Methods 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
108091092328 cellular RNA Proteins 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
238000004590 computer program Methods 0.000 description 3
239000000470 constituent Substances 0.000 description 3
230000002950 deficient Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
238000002372 labelling Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
201000005296 lung carcinoma Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
229940055729 papain Drugs 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
230000003652 pro-growth Effects 0.000 description 3
239000000376 reactant Substances 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
238000011285 therapeutic regimen Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
229960001322 trypsin Drugs 0.000 description 3
239000000439 tumor marker Substances 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
235000012431 wafers Nutrition 0.000 description 3
238000005406 washing Methods 0.000 description 3
QSLFDILMORXPKP-UHFFFAOYSA-N (3-methylimidazol-3-ium-1-yl)-methylsulfanylphosphinate Chemical compound CSP([O-])(=O)N1C=C[N+](C)=C1 QSLFDILMORXPKP-UHFFFAOYSA-N 0.000 description 2
SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000701832 Enterobacteria phage T3 Species 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
102100033299 Glia-derived nexin Human genes 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
101000598058 Homo sapiens Transmembrane protease serine 11D Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108010059912 LEX 032 Proteins 0.000 description 2
108010085895 Laminin Proteins 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
101100069392 Mus musculus Gzma gene Proteins 0.000 description 2
MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
102100037591 Neuroserpin Human genes 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
208000034038 Pathologic Neovascularization Diseases 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102100035846 Pigment epithelium-derived factor Human genes 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
102100037681 Protein FEV Human genes 0.000 description 2
101710198166 Protein FEV Proteins 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
101710107115 Serine protease inhibitor 3 Proteins 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 2
108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 2
230000001668 ameliorated effect Effects 0.000 description 2
239000012491 analyte Substances 0.000 description 2
239000003098 androgen Substances 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
FSEKIHNIDBATFG-UHFFFAOYSA-N camostat mesylate Chemical compound CS([O-])(=O)=O.C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C([NH+]=C(N)N)C=C1 FSEKIHNIDBATFG-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
210000003711 chorioallantoic membrane Anatomy 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000003413 degradative effect Effects 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000001085 differential centrifugation Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000002060 fluorescence correlation spectroscopy Methods 0.000 description 2
238000002875 fluorescence polarization Methods 0.000 description 2
238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000001456 gonadotroph Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
102000014108 human airway trypsin-like protease Human genes 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
150000002611 lead compounds Chemical class 0.000 description 2
230000004807 localization Effects 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
229950002475 mesilate Drugs 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
230000006510 metastatic growth Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
108010080874 neuroserpin Proteins 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
229960003104 ornithine Drugs 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000037452 priming Effects 0.000 description 2
230000001023 pro-angiogenic effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
230000007065 protein hydrolysis Effects 0.000 description 2
230000006798 recombination Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000002165 resonance energy transfer Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
238000002821 scintillation proximity assay Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
238000000527 sonication Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000005026 transcription initiation Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000001086 yeast two-hybrid system Methods 0.000 description 2
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
PKBZGVVSSNNHGY-INTLEYBYSA-N (4-carbamimidoylphenyl) 4-[(e)-3-[(2-ethoxy-2-oxoethyl)-prop-2-enylamino]-2-methyl-3-oxoprop-1-enyl]benzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(/C=C(\C)C(=O)N(CC=C)CC(=O)OCC)=CC=C1C(=O)OC1=CC=C(C(N)=N)C=C1 PKBZGVVSSNNHGY-INTLEYBYSA-N 0.000 description 1
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
OWIZTYOMGVTSDP-TXOOBNKBSA-N (e)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid;hydrate;hydrochloride Chemical compound O.Cl.C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 OWIZTYOMGVTSDP-TXOOBNKBSA-N 0.000 description 1
VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
101150098072 20 gene Proteins 0.000 description 1
101150090724 3 gene Proteins 0.000 description 1
101150110188 30 gene Proteins 0.000 description 1
WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
101710163968 Antistasin Proteins 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010031480 Artificial Receptors Proteins 0.000 description 1
IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 description 1
101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 description 1
241001367049 Autographa Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
102400000748 Beta-endorphin Human genes 0.000 description 1
101800005049 Beta-endorphin Proteins 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101100067449 Caenorhabditis elegans fut-1 gene Proteins 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
101710169873 Capsid protein G8P Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
101710194146 Ecotin Proteins 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
101000829922 Escherichia phage Mu Putative capsid assembly protein F Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108010008177 Fd immunoglobulins Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical group NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
101710140489 Guamerin Proteins 0.000 description 1
108010043026 HGF activator Proteins 0.000 description 1
101000788071 Haemophilus phage HP1 (strain HP1c1) Putative tail protein gp30 Proteins 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
102100031465 Hepatocyte growth factor activator Human genes 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 1
101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 1
102400001240 Inter-alpha-trypsin inhibitor light chain Human genes 0.000 description 1
101710114613 Intracellular serine protease Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108010054278 Lac Repressors Proteins 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
101710180643 Leishmanolysin Proteins 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
101710156564 Major tail protein Gp23 Proteins 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
108010038049 Mating Factor Proteins 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
241000579835 Merops Species 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
102100030856 Myoglobin Human genes 0.000 description 1
108010062374 Myoglobin Proteins 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
OAIDYCIOARUBNS-WNQIDUERSA-N OC[C@H](N)C(O)=O.C1=CC=C2C(=O)OC=CC2=C1 Chemical compound OC[C@H](N)C(O)=O.C1=CC=C2C(=O)OC=CC2=C1 OAIDYCIOARUBNS-WNQIDUERSA-N 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
241000906034 Orthops Species 0.000 description 1
108090000417 Oxygenases Proteins 0.000 description 1
102000004020 Oxygenases Human genes 0.000 description 1
101150072055 PAL1 gene Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
BEPSGCXDIVACBU-IUCAKERBSA-N Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CN=CN1 BEPSGCXDIVACBU-IUCAKERBSA-N 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
101000802257 Pseudomonas phage D3112 Anti-CRISPR protein 30 Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
102000000395 SH3 domains Human genes 0.000 description 1
108050008861 SH3 domains Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
241000253973 Schistocerca gregaria Species 0.000 description 1
241000242683 Schistosoma haematobium Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102100021117 Serine protease HTRA2, mitochondrial Human genes 0.000 description 1
101710146118 Serine protease HTRA2, mitochondrial Proteins 0.000 description 1
108010005113 Serpin E2 Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010069102 Thromboxane-A synthase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
RDFCSSHDJSZMTQ-ZDUSSCGKSA-N Tos-Lys-CH2Cl Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 RDFCSSHDJSZMTQ-ZDUSSCGKSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
102100032471 Transmembrane protease serine 4 Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
101150117115 V gene Proteins 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
238000003314 affinity selection Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
229960000711 alprostadil Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
238000005284 basis set Methods 0.000 description 1
108010065944 bdellastasin Proteins 0.000 description 1
230000008901 benefit Effects 0.000 description 1
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
229960000772 camostat Drugs 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
238000001386 capillary affinity electrophoresis Methods 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
108020001778 catalytic domains Proteins 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007806 chemical reaction intermediate Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229940043292 chymotrypsin / trypsin Drugs 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
238000002742 combinatorial mutagenesis Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
108010075231 contrapsin Proteins 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011613 copenhagen rat Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000014155 detection of activity Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000007878 drug screening assay Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000010408 film Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
210000001559 fluids and secretion Anatomy 0.000 description 1
238000000198 fluorescence anisotropy Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
229950000501 gabexate Drugs 0.000 description 1
DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000004368 gonadotroph Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000014726 immortalization of host cell Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000001689 kallikreinlike Effects 0.000 description 1
108010079923 lambda Spi-1 Proteins 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000004576 lipid-binding Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
238000000504 luminescence detection Methods 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000000723 mammalian artificial chromosome Anatomy 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
SKEFKEOTNIPLCQ-LWIQTABASA-N mating hormone Chemical group C([C@@H](C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCS(C)=O)C(=O)NC(CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CN=CN1 SKEFKEOTNIPLCQ-LWIQTABASA-N 0.000 description 1
230000035800 maturation Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
108010065781 myosin light chain 2 Proteins 0.000 description 1
YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100001221 nontumorigenic Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
101150093139 ompT gene Proteins 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229950003837 ozagrel Drugs 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
108010079892 phosphoglycerol kinase Proteins 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
108090000102 pigment epithelium-derived factor Proteins 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
239000005373 porous glass Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
238000001814 protein method Methods 0.000 description 1
238000002005 protein protein interaction detection Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000002762 protein-protein interaction assay Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
229940124553 radioprotectant Drugs 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
108700024098 rat LOC299282 Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
239000012508 resin bead Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
239000013049 sediment Substances 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000010008 shearing Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004557 single molecule detection Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000003746 solid phase reaction Methods 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002381 testicular Effects 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
108010003137 tyrosyltyrosine Proteins 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037314 wound repair Effects 0.000 description 1